Company profile ATXS
There is not enough data for Astria Therapeutics -clinical development to provide analysis
There is not enough data for Astria Therapeutics -clinical development to provide correlation calculation
There is not enough data for Astria Therapeutics -clinical development to provide analysis
There is not enough data for Astria Therapeutics STAR-0215 to provide analysis
There is not enough data for Astria Therapeutics STAR-0215 to provide correlation calculation
There is not enough data for Astria Therapeutics STAR-0215 to provide analysis
After 39 days of this quarter the interest is at 129.0. Based on that we can calculate that during remaining 52 days it will total up to 301.0. hereditary angioedema treatment expected interest is significantly higher compared to previous quarter (+356.1%) and same quarter last year (+258.3%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 23 | 33 43.5% QoQ | 100 203.0% QoQ | 60 -40.0% QoQ |
| 2020 | 32 39.1% YoY -46.7% QoQ | 43 30.3% YoY 34.4% QoQ | 54 -46.0% YoY 25.6% QoQ | 57 -5.0% YoY 5.6% QoQ |
| 2021 | 111 246.9% YoY 94.7% QoQ | 82 90.7% YoY -26.1% QoQ | 56 3.7% YoY -31.7% QoQ | 73 28.1% YoY 30.4% QoQ |
| 2022 | 61 -45.0% YoY -16.4% QoQ | 35 -57.3% YoY -42.6% QoQ | 98 75.0% YoY 180.0% QoQ | 81 11.0% YoY -17.3% QoQ |
| 2023 | 84 37.7% YoY 3.7% QoQ | 57 62.9% YoY -32.1% QoQ | 20 -79.6% YoY -64.9% QoQ | 66 -18.5% YoY 230.0% QoQ |
| 2024 | 129 53.6% YoY 95.5% QoQ | - | - | - |
The average 5 years interest of hereditary angioedema treatment was 5.19 per week. The last year interest of hereditary angioedema treatment compared to the last 5 years has changed by 22.93%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 39.91%.
There is not enough data for monoclonal antibody inhibitor to provide analysis
There is not enough data for monoclonal antibody inhibitor to provide correlation calculation
There is not enough data for monoclonal antibody inhibitor to provide analysis
There is not enough data for plasma kallikrein to provide analysis
There is not enough data for plasma kallikrein to provide correlation calculation
There is not enough data for plasma kallikrein to provide analysis
After 39 days of this quarter the interest is at 248.0. Based on that we can calculate that during remaining 52 days it will total up to 579.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 563 | 733 30.2% QoQ | 706 -3.7% QoQ | 735 4.1% QoQ |
| 2020 | 770 36.8% YoY 4.8% QoQ | 537 -26.7% YoY -30.3% QoQ | 507 -28.2% YoY -5.6% QoQ | 524 -28.7% YoY 3.4% QoQ |
| 2021 | 577 -25.1% YoY 10.1% QoQ | 543 1.1% YoY -5.9% QoQ | 489 -3.6% YoY -9.9% QoQ | 535 2.1% YoY 9.4% QoQ |
| 2022 | 722 25.1% YoY 35.0% QoQ | 672 23.8% YoY -6.9% QoQ | 600 22.7% YoY -10.7% QoQ | 639 19.4% YoY 6.5% QoQ |
| 2023 | 740 2.5% YoY 15.8% QoQ | 658 -2.1% YoY -11.1% QoQ | 565 -5.8% YoY -14.1% QoQ | 656 2.7% YoY 16.1% QoQ |
| 2024 | 248 -66.5% YoY -62.2% QoQ | - | - | - |
The average 5 years interest of rare diseases was 48.73 per week. The last year interest of rare diseases compared to the last 5 years has changed by 0.29%. The interest for rare diseases is seasonal. The last year interest is quite lower compared to 5 years ago. It has decreased by -16.79%.
After 39 days of this quarter the interest is at 139.0. Based on that we can calculate that during remaining 52 days it will total up to 324.0. immunological diseases expected interest is significantly higher compared to previous quarter (+227.3%) and same quarter last year (+449.2%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 40 | 118 195.0% QoQ | 68 -42.4% QoQ | 21 -69.1% QoQ |
| 2020 | 68 70.0% YoY 223.8% QoQ | 83 -29.7% YoY 22.1% QoQ | 105 54.4% YoY 26.5% QoQ | 10 -52.4% YoY -90.5% QoQ |
| 2021 | 107 57.4% YoY 970.0% QoQ | 82 -1.2% YoY -23.4% QoQ | 110 4.8% YoY 34.1% QoQ | 71 610.0% YoY -35.5% QoQ |
| 2022 | 108 0.9% YoY 52.1% QoQ | 87 6.1% YoY -19.4% QoQ | 94 -14.5% YoY 8.0% QoQ | 67 -5.6% YoY -28.7% QoQ |
| 2023 | 59 -45.4% YoY -11.9% QoQ | 79 -9.2% YoY 33.9% QoQ | 54 -42.6% YoY -31.6% QoQ | 99 47.8% YoY 83.3% QoQ |
| 2024 | 139 135.6% YoY 40.4% QoQ | - | - | - |
The average 5 years interest of immunological diseases was 6.39 per week. The last year interest of immunological diseases compared to the last 5 years has changed by 15.49%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 27.46%.
There is not enough data for biological pharmaceutical company to provide analysis
There is not enough data for biological pharmaceutical company to provide correlation calculation
There is not enough data for biological pharmaceutical company to provide analysis
After 39 days of this quarter the interest is at 0.0. Based on that we can calculate that during remaining 52 days it will total up to 0.0. Catabasis Pharmaceuticals expected interest is significantly lower compared to previous quarter (-100.0%) and same quarter last year (-100.0%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 0 | 61 inf% QoQ | 16 -73.8% QoQ | 77 381.2% QoQ |
| 2020 | 66 inf% YoY -14.3% QoQ | 92 50.8% YoY 39.4% QoQ | 146 812.5% YoY 58.7% QoQ | 161 109.1% YoY 10.3% QoQ |
| 2021 | 195 195.5% YoY 21.1% QoQ | 137 48.9% YoY -29.7% QoQ | 40 -72.6% YoY -70.8% QoQ | 52 -67.7% YoY 30.0% QoQ |
| 2022 | 64 -67.2% YoY 23.1% QoQ | 101 -26.3% YoY 57.8% QoQ | 30 -25.0% YoY -70.3% QoQ | 43 -17.3% YoY 43.3% QoQ |
| 2023 | 27 -57.8% YoY -37.2% QoQ | 56 -44.6% YoY 107.4% QoQ | 64 113.3% YoY 14.3% QoQ | 151 251.2% YoY 135.9% QoQ |
| 2024 | 0 -100.0% YoY -100.0% QoQ | - | - | - |
The average 5 years interest of Catabasis Pharmaceuticals was 6.05 per week. The last year interest of Catabasis Pharmaceuticals compared to the last 5 years has changed by -5.29%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 56.99%.
There is not enough data for Astria Therapeutics Boston to provide analysis
There is not enough data for Astria Therapeutics Boston to provide correlation calculation
There is not enough data for Astria Therapeutics Boston to provide analysis